Hims & Hers Health (HIMS) to Release Earnings on Monday

Hims & Hers Health (NYSE:HIMS) will likely be issuing its quarterly earnings data after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $469.68 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $60.41 on Monday. The stock has a market cap of $13.20 billion, a price-to-earnings ratio of 137.31 and a beta of 1.35. The stock has a 50 day moving average price of $32.06 and a 200-day moving average price of $24.30. Hims & Hers Health has a one year low of $9.22 and a one year high of $64.84.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. TD Cowen reiterated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Piper Sandler boosted their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $25.13.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 2,343 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the sale, the insider now directly owns 165,254 shares in the company, valued at approximately $4,941,094.60. This represents a 1.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the transaction, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,052,332 shares of company stock worth $32,620,497. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.